Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04619823
Other study ID # 2019-062
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 15, 2021
Est. completion date February 15, 2026

Study information

Verified date September 2022
Source Institut Pasteur
Contact Myrielle Dupont-Rouzeyrol, PhD
Phone +687 27 75 30
Email mdupont@pasteur.nc
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Arboviruses, diseases transmitted to humans by the bite of an insect vector, are a major public health problem, particularly in tropical and sub-tropical countries. In New Caledonia, dengue epidemics are recurrent and may be associated with the co-circulation of other arboviruses such as Zika or chikungunya. The virological determinants which condition the occurrence of these epidemics may be linked to an increased vectorial competence of the vector mosquito Aedes aegypti for a particular viral isolate. In fact, the Aedes aegypti mosquito is infected by making a blood meal on a person infected with an arbovirus. The virus infects its digestive tract, then spreads throughout the mosquito's body until it reaches its salivary glands. The virus is then present in the saliva and will be injected into the human host during a new blood meal. Some viral variants are best transmitted by Aedes aegypti. In general, the study of this vectorial competence is carried out by experiments in the laboratory during which an artificial blood meal composed of mammalian blood (human, rabbit, etc.) is mixed with a viral stock. Carrying out deported blood meals during which blood collected from patients infected with an arbovirus is used to gorge mosquitoes makes it possible to place oneself in experimental conditions as close as possible to the natural cycle of transmission of arboviruses. In the human host, cells of the myeloid lineage present in the peripheral blood constitute preferred targets of replication for arboviruses. At the same time, the peripheral blood cells of patients are activated in response to infection and secrete many soluble factors released into the blood of patients. The study of blood samples from patients infected with arboviruses is therefore of prime importance for understanding both the replicative mechanisms of arboviruses but also the immune response they induce.


Description:

Collection of blood samples from adult patients with clinical signs suggestive of arbovirus This study is a interventional study that present minimal risks and constraints. This study will improve : - the reliability of the results of vector competence experiments - the understanding of the mechanisms of infection and replication of arboviruses - the knowledge of the immune mechanisms involved in the response to infection by an arbovirus


Recruitment information / eligibility

Status Recruiting
Enrollment 250
Est. completion date February 15, 2026
Est. primary completion date February 15, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Major patient - Patient with clinical signs suggestive of an arbovirus infection: Fever And at least 2 clinical signs suggestive of arbovirus among which myalgia, retro-orbital pain, drop in platelets (if data available), digestive symptoms, etc. - Appearance of clinical signs suggestive of an arbovirus infection in the 7 days preceding the blood sample. - Patient informed of the performance of the research, the collection of data and biological samples - Patient who has given their consent to participate in the research by authorizing the collection of data, the collection of an additional blood sample and the use of this sample Exclusion Criteria: - Patient suffering from another identified virosis, an inflammatory disease or taking anti-inflammatory drugs - Pregnant patient - Patient returning from a trip within 15 days before the onset of the signs, - Patient for whom the blood sample is incomplete or could not be performed - Patient's condition, which, in the doctor's opinion, is incompatible with the additional sample required by the study - Patient not having consented to participate in the research

Study Design


Intervention

Other:
Blood sample collection
Blood sample collection Mosquito collection at home

Locations

Country Name City State
New Caledonia Centre Hospitalier Territorial de Nouvelle-Calédonie Dumbéa Sur Mer

Sponsors (3)

Lead Sponsor Collaborator
Institut Pasteur Centre Hospitalier Territorial de Nouvelle-Calédonie, Institut Pasteur de Nouvelle-Calédonie

Country where clinical trial is conducted

New Caledonia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measurement of vector competence parameters of Aedes aegypti (carriers or not of Wolbachia) for arboviruses by vector competence experiments using deported blood meals. Rate of infection of Aedes aegypti (carriers or not of Wolbachia) for arboviruses 5 years
Primary Measurement of vector competence parameters of Aedes aegypti (carriers or not of Wolbachia) for arboviruses by vector competence experiments using deported blood meals. Measurement of dissemination of Aedes aegypti (carriers or not of Wolbachia) for arboviruses 5 years
Primary Measurement of vector competence parameters of Aedes aegypti (carriers or not of Wolbachia) for arboviruses by vector competence experiments using deported blood meals. Measurement of transmission of Aedes aegypti (carriers or not of Wolbachia) for arboviruses 5 years
Secondary Molecular characterization of arborviruses strains included in the blood of patients and which may be diffused by mosquitoes carrying Wolbachia or not during deported blood meals Whole genome sequencing and bioinformatics techniques as well as by in vitro infections of arbovirus strains included in the blood of patients and which may be diffused by mosquitoes carrying Wolbachia or not during deported blood meals 5 years
Secondary Molecular characterization of arborviruses strains contained in mosquitoes present in patients' homes Whole genome sequencing and bioinformatics techniques as well as by in vitro infections of arbovirus strains contained in mosquitoes present in patients' homes 5 years
See also
  Status Clinical Trial Phase
Completed NCT05321264 - Educational Intervention to Promote Control Behaviors and Prevention of Dengue N/A
Completed NCT01436396 - Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Phase 3
Completed NCT01391819 - Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children N/A
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT02833584 - Safety of Paracetamol as Antipyretic in Treatment of Dengue Infection in Adults N/A
Completed NCT02433652 - Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2 Phase 1
Enrolling by invitation NCT02016027 - Pharmacological Effect of Carica Papaya Leaves Mother Tincture in Healthy Individuals Blood Parameter Phase 1
Completed NCT01477671 - Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children N/A
Recruiting NCT00377754 - Prospective Study of Infant Dengue N/A
Recruiting NCT05919277 - A Dengue Sero-prevalence Study in the Metropolitan Area of Buenos Aires
Recruiting NCT04582474 - Demonstration of an Electronic Clinical Decision Support Module for Dengue in Burkina Faso N/A
Completed NCT01983553 - Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
Completed NCT03803618 - Dengue Effectiveness Study in the Philippines
Active, not recruiting NCT05967455 - Homologous Re-infection With Dengue 1 or Dengue 3 Phase 1
Completed NCT03631719 - Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
Recruiting NCT02606019 - The Use of Biomarkers in Predicting Dengue Outcome N/A
Completed NCT02372175 - Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain Phase 1
Active, not recruiting NCT01696422 - Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine Phase 2
Completed NCT00993447 - Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Phase 2
Completed NCT00375726 - Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults Phase 1